A “life-saving” drug heavily subsidised for Australians living with opioid dependency will be pulled from the market by the end of the year, causing alarm among doctors and pharmacists.
US pharmaceutical company Indivior confirmed the marketing and sale of the long-acting injectable prescription opioid Sublocade would end from 31 December, with a company spokesperson describing it as a “commercial decision”.
